Cell therapy may slow kidney damage from type 2 diabetes
University of Galway, in collaboration with the NEPHSTROM Consortium, has announced promising results from a new cell therapy trial for people living with diabetes.
Dec 20, 2022
0
6
University of Galway, in collaboration with the NEPHSTROM Consortium, has announced promising results from a new cell therapy trial for people living with diabetes.
Dec 20, 2022
0
6
Since December 2019, more than 60 million people have been diagnosed with coronavirus disease 2019 (COVID-19) worldwide, while approximately six million individuals have died as a result of the disease. Hospital treatment ...
Dec 20, 2022
0
3
A study by Oregon State University College of Pharmacy researchers suggests that two anticonvulsants often prescribed for chronic pain are only "modestly effective" at pain management and can create an unfavorable risk/reward ...
Dec 19, 2022
0
27
Osteoarthritis is a common chronic condition that usually causes joint pain and can be severe enough to require knee and hip replacements. In the United States, the number of total knee replacement (TKR) and total hip replacement ...
Dec 19, 2022
0
32
Not all pediatric patients with type 2 diabetes have obesity, according to a systematic review and meta-analysis published online Dec. 15 in JAMA Network Open.
Dec 17, 2022
0
2
The American Diabetes Association on Monday released new standards of care to reflect changes in technology, improved medications and a deeper understanding of the social factors that contribute to disease and diabetes control.
Dec 13, 2022
0
12
A large-scale new study offers a new approach to treating in type 2 diabetes, one that puts patients in charge of their own medication. The Trimaster study is the first to allow people with type 2 diabetes to choose their ...
Dec 7, 2022
0
29
People with diabetes are benefiting from advances in medications and technologies to lower their risk of hypoglycemia, according to a Clinical Practice Guideline issued today by the Endocrine Society.
Dec 7, 2022
0
40
For patients with diabetes subsequently diagnosed and hospitalized with COVID-19, use of a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) before COVID-19 infection is associated with lower COVID-19-related adverse outcomes, ...
Dec 7, 2022
0
9
Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced the risk for hospitalization for any cause in patients with chronic kidney disease (CKD) with and without type 2 diabetes. The findings suggest that ...
Dec 6, 2022
0
5